Thyroid Eye Disease clinical trials at UCSF

2 in progress, 1 open to eligible people

Thyroid eye disease affects the eyes and can cause them to bulge or become red. UCSF is studying a new treatment called batoclimab to see if it helps reduce symptoms. Participants will get the medicine once a week for 12 weeks.

Showing trials for

  • Batoclimab in Participants With Active Thyroid Eye Disease

    open to eligible people ages 18 years and up

    To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

    San Francisco, California and other locations

  • Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( THRIVE )

    Sorry, in progress, not accepting new patients

    Please note that Phase 1/2 (HV &amp ; TED MAD) cohorts and Phase 3 component (THRIVE) - recruitment is complete. The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of veligrotug (VRDN-001) in healthy volunteers (HV) and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.

    San Francisco, California and other locations

Last updated: